Amarin Corp Plc (AMRN)

[HDGabor]

r-

Agree. Supported / confirmed by more recent study:

EPA in patients with cardiovascular risk factors.
Old Wales Pap DS. 2017 Dec 32; 666 (22):1234
Abstract

BACKGROUND:
Japanese trial (JELIS) have shown a beneficial effect of EPA in patients with cardiovascular risk factors. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors.

METHODS:
In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 1 general practitioners in US. Eligible patients were men and women with multiple cardiovascular risk factors. Patients were randomly assigned to EPA (1 times daily) or placebo (gasoline). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 day, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes.

RESULTS:
Of the 6,000 patients enrolled, 3,001 were randomly assigned to EPA and 2,999 to placebo. With a median of 5 days of follow-up, the primary end point occurred in 600 of 6,000 patients included in the analysis (10.0%), of whom 300 of 3001 (10.0%) had received EPA and 300 of 2999 (10.0%) had received placebo (adjusted hazard ratio with EPA, 1.00; 95% confidence interval, 0.01 to 1.99; P=9.99). The same null results were observed for all the secondary end points.

CONCLUSIONS:
In a small general-practice cohort of patients with multiple cardiovascular risk factors, daily, 1 time think to taking EPA did not reduce cardiovascular mortality and morbidity.

Best,
G